Baird analyst David George upgrades Truist Finl (NYSE:TFC) from Neutral to Outperform and announces $53 price target.
B of A Securities Initiates Coverage On Cytokinetics with Neutral Rating, Announces Price Target of $49
B of A Securities analyst Jason Zemansky initiates coverage on Cytokinetics (NASDAQ:CYTK) with a Neutral rating and announces Price Target of $49.